The remote patient monitoring technology from Alio Medical has received FDA approval and now includes the three new metrics of hematocrit, hemoglobin, and potassium.
The platform comprises of a SmartPatch™, hub, and portal that allow care teams to non-invasively collect clinical-grade parameters. By issuing actionable notifications, Alio enables patients and their care teams to continuously check their condition.
The SmartPatch can now be used to monitor important parameters like skin temperature, auscultation, heart rate, hematocrit, hemoglobin, and potassium after this approval.
The company's initial area of focus is individuals with end-stage kidney disease, even though the technology can be used to monitor a variety of chronic illnesses. (ESKD).
Up until now, patients on dialysis and their care teams have experienced limited progress in care management and the development of innovative solutions.
Hospitalizations present a particular threat for End-Stage Kidney Disease (ESKD) patients. Issues such as fluid overload and dyskalemia can lead to serious health problems, yet the current standard of care for monitoring such conditions is limited to infrequent blood draws each month. Fortunately, the Alio SmartPatch offers a revolutionary solution. This device provides accurate and painless readings of crucial variables every few hours, allowing for detailed and sustained monitoring of a patient’s health.